Ventyx Biosciences
VTYX
Performance
About Ventyx Biosciences
Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases. The company leverages medicinal chemistry, structural biology, and immunology to discover differentiated small-molecule therapeutics for conditions with high unmet medical need, advancing them through clinical trials. Its lead portfolio includes NLRP3 inhibitors such as VTX2735 (peripherally restricted) and VTX3232 (CNS-penetrant) in Phase 2 development, along with tamuzimod (S1P1R modulator) and VTX958 (TYK2 inhibitor) in various stages of clinical testing.
Recent News
Lilly Bulks Up Inflammatory Pipeline With $1.2B Ventyx Buy, InduPro Cancer Pact
Deals Not Waiting for JPM
Lilly Establishes up to $2.7B Repertoire Deal in Second Immune Play of 2026
Accertify Names Dukat CEO, Adds to Leadership Team
Biotech’s Next Chapter: Asset-Centric Deals and Shifting Alpha at JPM 2026
Lilly Acts on ‘Expansion Plans’ in Neuroscience, Immunology via $1.2B Ventyx Takeout
Lilly Was the only Pharma Bidder for Ventyx
Lilly Snaps up Ventyx for $1.2B in Pursuit of Oral Immune Drugs
